Nova Signal specializes in advanced medical imaging technologies, particularly focusing on noninvasive monitoring of cerebral hemodynamics through their NeuraSignal Platform. This platform utilizes Transcranial Doppler (TCD) ultrasound, a painless method that employs high-frequency sound waves to assess blood flow in the brain. The NG2 Intelligent Ultrasound system enhances this process by integrating artificial intelligence and robotics, allowing for real-time assessments that improve clinical decision-making. The technology is designed to detect conditions such as right-to-left shunts and emboli with a significantly higher accuracy compared to traditional methods, thereby facilitating timely interventions and better patient outcomes.

The NeuraSignal Platform is not only portable and suitable for bedside use but also adheres to stringent regulatory standards, including FDA regulations and ISO certifications. By automating the identification of optimal imaging windows and employing advanced algorithms, the system mimics the expertise of human technicians while providing rapid and precise data. This innovation aims to reduce the need for more invasive procedures, lower healthcare costs, and enhance the overall efficiency of stroke care, ultimately leading to improved patient satisfaction and reduced hospital readmissions.

United States

In 2023 NeuraSignal, Inc. acquired the business of NovaSignal, the original developer of NovaGuide. NeuraSignal is a medical technology company with a mission to save lives by unlocking the power of cerebral blood flow data. The company's FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time. Using cloud computing and data analytics, NeuraSignal supports physicians in their clinical decision making in several neurological conditions including stroke, traumatic brain injury, and dementia. To learn more, visit www.NeuraSignal.com.

Nova Signal

Company Details